Navigation Links
FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Date:3/18/2008

tion of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov <http://www.sec.gov>, http://www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
3. HHS Issues First Department-Wide Report on Personalized Health Care
4. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
5. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
8. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
9. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... ) today announced data from PERSIST-1 – a randomized ... of myelofibrosis – in a late-breaking oral session at ... of Clinical Oncology (ASCO), May 29-June 2, 2015 in ... investigational oral multikinase inhibitor with specificity for JAK2 and ...
(Date:5/29/2015)... HILL, N.C. , May 29, 2015 /PRNewswire/ ... medical affairs function into roles involving clinical development, ... As its responsibilities have grown, Medical Affairs has ... function as a global group. And while its ... find it challenging to identify strong performance metrics ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
(Date:5/29/2015)... Market Publishers Ltd and Shanghai ... partnership agreement for quality market research promotion on ... sell research reports worked out by Chem-Report. , ... upon the agreement: “Chem-Report is a Chinese company ... chemical markets on global and country levels. The ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3
... research team co-led by scientists from the J. Craig Venter ... of Maryland School of Medicine, today published the sequence and ... in Nature Biotechnology . Agnes P. Chan, Ph.D., JCVI, ... paper describing the 4.5X coverage of this important oilseed crop. ...
... In Vitro Toxicology Services -- MACCLESFIELD, England, August 20, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... SLN), a leading international RNAi therapeutics company, is pleased ... has announced the grant of an option to Novartis ... commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which ... conducting a Phase II clinical trial of QPI-1002 for ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Cyprotex Adds In Vitro Toxicology Services 2Cyprotex Adds In Vitro Toxicology Services 3Cyprotex Adds In Vitro Toxicology Services 4Cyprotex Adds In Vitro Toxicology Services 5Cyprotex Adds In Vitro Toxicology Services 6Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... developing bipolar disorder depends in part on the combined, small ... brain, none of which is powerful enough to cause the ... the enzyme produced by one of these genes could lead ... was conducted by scientists at the National Institutes of Health's ...
... their effects on fat development, researchers have discovered that ... mice without some of the side effects attributed to ... harmine, was first isolated more than 150 years ago ... around the world, the team reports in the May ...
... it express who we are, but is it really possible to ... to that question seems to be related to fashion and glamour, ... Mexico and the Buck Institute in the USA, were able to ... In biology, the capacity to establish the function of a molecule, ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3Fat screen delivers plant-derived chemical with antidiabetic effects 2
... Helios gene gun system, 220-240 V, is ... into cells. This handheld device employs an ... and other biomaterial-coated gold microcarriers from the ... directly into target cells. This system has ...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... a DNA sequencing service. We can sequence ... products, BACs, etc. Our DNA sequencing service ... plasmids or purified PCR products. We use ... automated reaction setup and dye terminator removal. ...
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Biology Products: